Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib for COVID-19 Pneumonia
NCT04331665Terminated
- Sponsor
- University Health Network
- Start
- May 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of ruxolitinib in COVID-19 pneumonia, sponsored by University Health Network. Primary endpoints: Proportion of patients with COVID-19 pneumonia who become critically ill at 6 months and Number of adverse events at 9 months. Started May 2020; status: terminated.
02
Drugs
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04331665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04331665.